Please assess the completion status of the following clinical trial:

Trial Title: Study of the Insomnia in Patients With Low Back Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* • Diagnosis of insomnia based on DSM-IV criteria for insomnia due to a general medical condition (low-back pain);~  * The insomnia must not predate the onset of low-back pain by more than 1 month;~ * Usual nightly TST (Total Sleep Time) \< 6.5 hours and/or usual SOL (Sleep Onset Latency) \> 30 minutes for the last month prior to screening;~ * ISI (Insomnia Severity Index) \> 14 (at least moderate insomnia);~ * Age 21-64 years;~ * Greater than 40 on VAS (Visual Analog Scale) for pain (scale is 0-no pain to 100-worst imaginable pain);~ * Patient Global Impression of Pain of at least 3 (on a 1-5 scale, indicating at least moderate severity);~ * reported Back pain must be greater than reported leg pain, and there must be no signs of spinal nerve root compression;~ * presence of normal motor strength on exam;~ * duration of chronic low back pain of greater than three months;~ * low back pain location must be inferior to T12 and superior to the gluteal fold.~Exclusion Criteria:~* • Significant medical or neurological illness in excess of that which is directly responsible for the chronic low back pain;~  * the presence of an active and significant psychiatric disease with a substantive impact on sleep;~ * meeting DSM-IV criteria for an Axis I disorder within the last three months, or meeting criteria for substance abuse within the last 12 months;~ * current pregnancy; history of hypersensitivity, intolerance, or contraindication to Naproxen/Lansoprazole or Eszopiclone;~ * baseline creatinine of 2.0 or greater; patient taking other medications having significant renal effects (e.g. lithium, ACE inhibitor, angiotensin receptor antagonist, or thiazide/loop diuretics);~ * patients taking other anticoagulants; patients having an allergy to aspirin; history of diagnosed gastric or duodenal ulcer;~ * history of bleeding or clotting diathesis; lifetime history of myocardial infarction or cerebrovascular accident;~ * Elevated PT/PTT/INR (Prothrombin Time, Partial Thromboplastin Time, International Normalized Ratio)at screening;~ * Abnormal kidney function detected in screening labs;~ * history of back related surgery within the past 3 months; history of corticosteroid use in the past 30 days;~ * presence of currently pending litigation or worker's compensation claim related to the chronic low back pain;~ * inability to follow study procedures or complete the study; or the use of any medications that could affect sleep within 5 half-lives of screening;~ * history of back surgery within the past 2 years with the exception of a discectomy;~ * pregnant or lactating females;~ * women of child-bearing potential who will not agree to use approved means of birth control during the trial;~ * history of any surgery within the past one month; history of any major physical trauma within the last 6 months;~ * history of corticosteroid use within the last 90 days; diagnosis of rheumatoid or psoriatic arthritis;~ * history of fibromyalgia;~ * presence of spondyloarthropathy;~ * presence of sciatica;~ * spinal stenosis;~ * presence of any vertebral fractures, spondylolisthesis; or radicular back pain.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: PLACEBO_COMPARATOR): Placebo
- 2 (Type: ACTIVE_COMPARATOR): Eszopiclone

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete